摘要
组蛋白去乙酰化酶(HDAC)异常高表达促进多种肿瘤的增殖、侵袭和转移,是新近鉴定的抗三阴性乳腺癌(TNBC)治疗靶点。近年来已研发多种HDAC抑制剂广泛用于抗肿瘤基础研究与临床治疗。本文综述了HDAC家族蛋白参与TNBC发生的分子机制和HDAC抑制剂用于抗TNBC治疗的研究进展,讨论了目前HDAC抑制剂的局限性、未来研发方向和以HDAC为靶点的抗TNBC研究新策略。
Abnormal high expression of histone deacetylase(HDAC)promotes malignant proliferation of many kinds of tumor and has been identified as a new target for anti-triple negative breast cancer(TNBC)therapy.In view of the important role of HDACs played in tumorigenesis,a variety of HDAC inhibitors have been developed and widely used in basic research and clinical treatment of cancer.This paper reviewes the latest research progress of HDAC about TNBC generation,development and potential application of HDAC inhibitor in anti-TNBC therapy.
作者
王发玲
谢珂
王艳林
曹春雨
WANG Fa-ling;XIE Ke;WANG Yan-lin;CAO Chun-yu(Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy,Medical College of China Three Gorges University,Yichang 443002,China)
出处
《基础医学与临床》
CSCD
2018年第11期1625-1629,共5页
Basic and Clinical Medicine
基金
国家自然科学基金(81372265
81772833)
宜昌市科学研究与开发项目(A17-301-23)
风湿性疾病发生与干预湖北省重点实验室开放项目(OIR13012A)
